SHPH
Shuttle Pharmaceuticals Holdings Inc
$
2.500
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
2.5094
Open
2.480
VWAP
2.36
Vol
84.44K
Mkt Cap
2.68M
Low
2.2455
Amount
199.05K
EV/EBITDA(TTM)
--
Total Shares
16.79M
EV
-1.70M
EV/OCF(TTM)
--
P/S(TTM)
--
Shuttle Pharmaceuticals Holdings, Inc. is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Its product candidates include Ropidoxuridine, a Phase II, clinical-stage radiation sensitizer, a platform of HDAC inhibitors (SP-1-161, SP-2-225 and SP-1-303), and two preclinical, prostate cancer-oriented diagnostics assets: PC-RAD Test, a blood test to predict clinical response to radiation therapy and PSMA-B ligand for potential use as a theranostic agent. Ropidoxuridine (IPdR) is for use in combination with RT to treat brain tumors (glioblastoma) and sarcomas. SP-1-161 is a candidate lead of compounds demonstrating activation of the ATM gene product (mutated in Ataxia-Telangiectasia). SP-2-225 is a candidate lead of compounds demonstrating Class II (HDAC6) selective inhibition. SP-1-303 is a candidate Class I HDAC inhibitor with preferential efficacy against ER positive cancers.
Show More
Valuation Metrics
The current forward P/E ratio for Shuttle Pharmaceuticals Holdings Inc (SHPH.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Shuttle Pharmaceuticals Holdings Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.03
Current PS
2.50
Overvalued PS
0.35
Undervalued PS
-0.28
Financials
Annual
Quarterly
FY2025Q2
0.00
Total Revenue
FY2025Q2
YoY :
+163.75%
-3.91M
Operating Profit
FY2025Q2
YoY :
+82.48%
-3.71M
Net Income after Tax
FY2025Q2
YoY :
-86.36%
-3.29
EPS - Diluted
FY2025Q2
YoY :
+139.76%
-3.36M
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
2.6K
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
2.6K
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
SHPH News & Events
Events Timeline
2025-10-10 (ET)
2025-10-10
10:22:42
Shuttle Pharmaceuticals Reveals Extension of Letter of Intent with Molecule.ai
2025-10-09 (ET)
2025-10-09
16:23:14
Shuttle Pharmaceuticals to purchase Molecule.ai for $10 million
2025-06-12 (ET)
2025-06-12
12:01:37
Shuttle Pharmaceuticals says reverse stock split to become effective June 16
Sign Up For More Events
Sign Up For More Events
News
8.5
10-10NASDAQ.COMShuttle Pharmaceuticals Enters LOI to Purchase AI Drug Discovery Company Molecule.ai
8.5
10-10NewsfilterShuttle Signs Letter of Intent with Molecule.ai
8.5
10-09NewsfilterShuttle Set to Join $3.24 Billion AI-Driven Pharmaceutical Industry
Sign Up For More News
People Also Watch
FAQ
What is Shuttle Pharmaceuticals Holdings Inc (SHPH) stock price today?
The current price of SHPH is 2.5 USD — it has decreased -1.96 % in the last trading day.
What is Shuttle Pharmaceuticals Holdings Inc (SHPH)'s business?
What is the price predicton of SHPH Stock?
What is Shuttle Pharmaceuticals Holdings Inc (SHPH)'s revenue for the last quarter?
What is Shuttle Pharmaceuticals Holdings Inc (SHPH)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Shuttle Pharmaceuticals Holdings Inc (SHPH)'s fundamentals?
How many employees does Shuttle Pharmaceuticals Holdings Inc (SHPH). have?